--- a
+++ b/clusters/9knumclustersv2/clust_1093.txt
@@ -0,0 +1,53 @@
+Subjects with inactive central nervous system (CNS) metastasis are eligible..
+Active, untreated central nervous system (CNS) metastasis
+Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
+Symptomatic central nervous system (CNS) malignancy or metastasis.
+Have symptomatic central nervous system malignancy or metastasis.
+Have symptomatic central nervous system (CNS) malignancy or metastasis.
+Symptomatic central nervous system metastasis (e.g., patients requiring increasing doses of steroids)
+Have symptomatic central nervous system (CNS) malignancy (with the exception of medulloblastoma) or metastasis (screening not required).
+Central nervous system (CNS) metastasis.
+Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patients myeloma
+Central nervous system (CNS) metastasis
+About to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasis
+Central nervous system (CNS) metastasis
+Active (symptomatic) central nervous system (CNS) metastasis.
+Presence of untreated and/or symptomatic central nervous system (CNS) metastasis
+History of asymptomatic or symptomatic central nervous system (CNS) metastasis
+Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
+History of central nervous system (CNS) metastasis.
+Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patients myeloma
+Symptomatic central nervous system (CNS) metastasis.
+Symptomatic brain metastasis or uncontrolled central nervous system (CNS) metastasis will not be permitted
+Has active central nervous system (CNS) or leptomeningeal metastasis
+Have symptomatic central nervous system metastasis. Screening of asymptomatic participants is not required for enrollment.
+Central nervous system (CNS) metastasis.
+Have the presence of unstable central nervous system (CNS) metastasis.
+Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).
+Active or untreated central nervous system (CNS) metastasis
+Have clinical evidence or a history of central nervous system (CNS) metastasis
+Known untreated central nervous system (CNS) metastasis
+Symptomatic Central Nervous System (CNS) metastasis
+Central nervous system (CNS) metastasis
+Have symptomatic central nervous system (CNS) malignancy or metastasis. Screening of asymptomatic subjects without history of CNS metastases is not required.
+Symptomatic central nervous system (CNS) malignancy or metastasis.
+Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patients myeloma
+History of central nervous system (CNS) metastasis that are untreated or not stable
+Clinically unstable central nervous system (CNS) metastasis
+Clinical evidence of central nervous system (CNS) metastasis.
+For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
+Have active central nervous system (CNS) metastasis
+Symptomatic central nervous system disease, malignancy, or metastasis
+Known untreated central nervous system (CNS) metastasis
+Known central nervous system (CNS) disease except for treated brain metastasis
+Evidence of central nervous system (CNS) metastasis who have not received prior definitive therapy for their lesions.
+Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
+Patients with Central Nervous System (CNS) metastasis which are: symptomatic or require treatment for symptom control and/or growing
+Symptomatic central nervous system malignancy or metastasis (screening not required).
+Have symptomatic central nervous system (CNS) malignancy or metastasis
+Active untreated central nervous system (CNS) metastasis
+Known untreated central nervous system (CNS) metastasis; patients with CNS metastasis will be allowed on study once treated
+Known brain metastasis or primary central nervous system (CNS) malignancy
+Patient must not have untreated or symptomatic central nervous system (CNS) metastasis
+Have symptomatic central nervous system (CNS) malignancy or metastasis.
+Subjects with symptomatic brain metastasis or central nervous system (CNS) disease